- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Bausch + Lomb acquires eye surgery drug
Bausch + Lomb has concluded its worldwide acquisition of the assets and intellectual property for a proprietary injectable miotic pharmaceutical (Miochol-E, Novartis AG).
Rochester, NY-Bausch + Lomb has concluded its worldwide acquisition of the assets and intellectual property for a proprietary injectable miotic pharmaceutical (Miochol-E, Novartis AG).
Under the agreement, Bausch + Lomb will be provided technical assistance by Novartis to assist in the transfer of manufacturing.
“Closure of this acquisition is a terrific gain for Bausch + Lomb pharmaceuticals,” said Dan Wechsler, president, global pharmaceuticals, Bausch + Lomb.
The injectable miotic pharmaceutical “not only continues to diversify our ophthalmic portfolio, it allows patients to continue to benefit from this well-known product,” he added.
In most markets worldwide, only two injectable miotic products are available, of which the new acquisition is one, according to the company.
“We’re glad patients will continue to benefit from this broadly known product,” said Brent L. Saunders, chief executive officer, Bausch + Lomb.
